TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23544775
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for depression (specifics not provided, but benzodiazepines were used in 18% of patients)
Study: 17655565
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise therapy (PT)
Study: 7662225
Drug: enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (20 mg/day)
Study: 10070170
Drug: irbesartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: irbesartan (100 mg/day)
Study: 21966787
Drug: Vaginal tablets
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal tablets (ketoconazole 800 mg + clindamycin 100 mg)
Study: 21966787
Drug: Vaginal capsules
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal capsules (ketoconazole 800 mg + clindamycin 100 mg)
Study: 15528908
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil mouthrinse plus 100 mg/kg fluoride
Study: 9286238
Drug: Total paracentesis
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total paracentesis plus intravenous albumin (PARA)
Study: 20189472
Drug: Metoclopramide hydrochloride
Normalized name: Metoclopramide Hydrochloride
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide hydrochloride tablets
Study: 18022695
Drug: Urinary N(2)O
Normalized name: O-2-Naphthyl m,N-dimethylthiocarbanilate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary N(2)O >= 27 microg/l
Study: 18022695
Drug: Urinary N(2)O
Normalized name: O-2-Naphthyl m,N-dimethylthiocarbanilate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary N(2)O < 27 microg/l
Study: 18022695
Drug: Workers with
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workers with urinary N(2)O >= 27 microg/l
Study: 10628604
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of pancuronium (n = 14)
Study: 7862660
Drug: Plasma rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma rich in anti-HIV-1 antibody
Study: 2029920
Drug: Green light
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green light phototherapy (Sylvania F20T12/G)
Study: 19528841
Drug: sugar-free Red
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar-free Red Bull energy drink (2 mg x kg(‐1) body mass caffeine or approximately 147 mg caffeine; 4 kcal/250 mL)
Study: 19528841
Drug: noncaffeinated, sugar-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: noncaffeinated, sugar-free placebo (lemon-lime flavored soft drink, tonic water, lime juice; 4 kcal/250 mL)
Study: 17304888
Drug: 2.5% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% hydrocortisone in moisturizing cream
Study: 17304888
Drug: Moisturizing cream
Normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing cream alone
Study: 15802775
Drug: Various agents
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various agents for treatment and prevention of osteoporosis, specific agents not mentioned, duration not specified.
Study: 10233200
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rizatriptan
Study: 10233200
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg rizatriptan
Study: 10233200
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous rizatriptan
Study: 2383801
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg body weight followed by 2.5 mg/kg body weight 2 and 0.5 hours before exercise)
Study: 7054040
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids infusion
Study: 7054040
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid infusion
Study: 29108091
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose epinephrine (LDEPI) plus tranexamic acid (TXA)
Study: 29108091
Drug: Topical diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diluted epinephrine plus tranexamic acid (TXA)
Study: 24417761
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg · kg(‐1) loading dose over 10 min followed by 0.5 μg · kg(‐1) · h(‐1) infusion)
Study: 10782589
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (ID) 0.15 mL
Study: 10782589
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (IM) 1.0 mL
Study: 6813899
Drug: Butoctamide hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butoctamide hydrogen succinate (BAHS) 600 mg
Study: 23417317
Drug: Argireline applied
Normalized name: Argireline NP
DrugBank: Acetyl hexapeptide-3 (DB11709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argireline applied twice daily for 4 weeks
Study: 18200995
Drug: Arndt bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arndt bronchial blocker (ABB) for right-sided surgery
Study: 18200995
Drug: Arndt bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arndt bronchial blocker (ABB) for left-sided surgery
Study: 14990522
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy by general practitioners (5 to 7 sessions of 30 minutes each)
Study: 11548448
Drug: Losartan (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50-100 mg o.d.)
Study: 10087430
Drug: Warfarin managed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin managed by a nomogram
Study: 10087430
Drug: Standard warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard warfarin management by attending physicians
Study: 7921924
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus continuous oral chlorambucil (RT+CHL)
Study: 3139463
Drug: Follicle-stimulating hormone
Normalized name: Follicle-stimulating hormone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicle-stimulating hormone (FSH) (Metrodin, Serono Laboratories, Inc.)
Study: 31226717
Drug: Guided de-escalation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided de-escalation of dual antiplatelet treatment (DAPT)
Study: 29112565
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with oral antibiotics
Study: 21531233
Drug: Bare metal
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare metal stents followed by a 40-day prednisone treatment
Study: 16436648
Drug: Topiramate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (400 mg/day target dose)
Study: 15211369
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg orlistat per day (group 1; n=30)
Study: 15211369
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg orlistat plus 1700 mg metformin per day (group 2; n=27)
Study: 9477041
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (Daflon 500 mg = Dios), 2 tablets/day for 2 months
Study: 7888231
Drug: 160 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 micrograms rgp160 vaccine
Study: 7888231
Drug: 640 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 micrograms rgp160 vaccine
Study: 3345623
Drug: Nisoldipine (oral)
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine (oral)
Study: 3345623
Drug: Nisoldipine (intravenous)
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine (intravenous)
Study: 21371548
Drug: Gastroretentive tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroretentive tablet (GT)
Study: 21371548
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of GT with CT
Study: 16741654
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous thiamine
Study: 11913310
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 5% sodium bicarbonate (0 times daily - control)
Study: 11913310
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 5% sodium bicarbonate (1 time daily)
Study: 11913310
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 5% sodium bicarbonate (2 times daily)
Study: 11913310
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 5% sodium bicarbonate (3 times daily)
Study: 9744587
Drug: Pre and
Normalized name: MENTHOL 100 mg in 1 g TOPICAL CREAM [Dr. Teals Pre and Post Workout Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre and post prandial Duplex colour Doppler sonographic measurement of superior mesenteric artery (SMA) flow after a food challenge (200 ml of Ensure Plus)
Study: 9744587
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids introduced to patients with active Crohn's disease
Study: 8276648
Drug: LOW instantaneous
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW instantaneous dose rate (6 cGy/min single-dose)
Study: 8276648
Drug: HIGH instantaneous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH instantaneous dose rate (15 cGy/min single-dose)
Study: 8276648
Drug: Single-dose total-body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose total-body irradiation
Study: 8276648
Drug: Single-dose LOW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose LOW
Study: 8276648
Drug: Single-dose HIGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose HIGH
Study: 2663164
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg twice daily for two weeks, then 40 mg twice daily for three months)
Study: 2663164
Drug: Methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250 mg twice daily for two weeks, then 500 mg twice daily for three months)
Study: 8774
Drug: Hypertonic solutions
Normalized name: Hypertonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic solutions
Study: 8774
Drug: Hypertonic non-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic non-electrolyte solutions
Study: 26852499
Drug: Hyperbaric gaseous
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric gaseous cryotherapy in addition to traditional physical therapy, balneotherapy, therapeutic physical exercises, and massage.
Study: 26852499
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional physical therapy, balneotherapy, therapeutic physical exercises, and massage without hyperbaric gaseous cryotherapy).
Study: 16921043
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose chemotherapy (HDT)
Study: 16921043
Drug: Tandem high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem high-dose chemotherapy (HDT)
Study: 16921043
Drug: Complete remission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete remission after induction chemotherapy
Study: 15015647
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 mg/kg heparin)
Study: 9167099
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (30% daily energy intake) with one fish meal daily (3.6 g omega-3/day)
Study: 9167099
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (30% daily energy intake) without fish
Study: 1350232
Drug: Azelastine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine, 4 mg twice daily
Study: 21154036
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements to lower homocysteine
Study: 7745048
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with active agent or placebo placed in the peritoneal cavity
Study: 19840308
Drug: 308-nm Excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm Excimer laser treatment, applied twice a week for 12 weeks
Study: 19840308
Drug: Control patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patches (not treated with the 308-nm Excimer laser)
Study: 19840308
Drug: 308-nm Excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm Excimer laser treatment
Study: 18092260
Drug: Infliximab (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (standard dosage)
Study: 18092260
Drug: Infliximab (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (double dosage)
Study: 3392233
Drug: Nilvadipine 4
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 4 mg
Study: 3229870
Drug: Nilvadipine 12
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 12 mg
Study: 3229870
Drug: Nilvadipine 20
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 20 mg
Study: 31027060
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy (MT) for 30 minutes a day, 3 days a week for 4 weeks + conventional physical therapy
Study: 28652725
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg QD
Study: 24157144
Drug: Multimodal cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cocktail periarticular injection with steroid
Study: 24157144
Drug: Multimodal cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cocktail periarticular injection without steroid
Study: 21916908
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (counselling on osteoporosis, risk factors, lifestyle modifications, goals of therapy, side effects, and importance of adherence)
Study: 21916908
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (counselling)
Study: 3312450
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) inhalation aerosol
Study: 27873451
Drug: Piperacillin/tazobactam (PIPC/TAZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (PIPC/TAZ) 337.5 mg/kg per day in three doses, 1-hr DIV, maximum 13.5 g per day
Study: 27873451
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) 120 mg/kg per day in three doses, 1-hr DIV, maximum 3 g per day
Study: 24598216
Drug: Remifentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil with an effect-site target concentration of 3 ng/ml
Study: 12182258
Drug: IV ramosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ramosetron 0.15 mg
Study: 12182258
Drug: IV ramosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ramosetron 0.3 mg
Study: 12182258
Drug: IV ramosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ramosetron 0.6 mg
Study: 10448289
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen (TAM) 20 mg daily for 2 years
Study: 10448289
Drug: TAM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM plus one cycle of low-dose, short-term chemotherapy
Study: 24849193
Drug: Olmesartan medoxomil/hydrochlorothiazide
Normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) fixed-dose combination tablet
Study: 22999396
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400μg
Study: 17543781
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg everolimus
Study: 17543781
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg everolimus
Study: 15480108
Drug: Aldosterone inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone inhibitor (amiloride and hydrochlorothiazide)
Study: 8311218
Drug: Tegaderm dressing
Normalized name: Tegaderm Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaderm dressing with EMLA cream
Study: 2571116
Drug: Clonidine-desipramine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine-desipramine combination
Study: 778302
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated influenza A/England/42/72 (H3N2) vaccine
Study: 26318350
Drug: Acellular diphtheria-tetanus-pertussis
Normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular diphtheria-tetanus-pertussis vaccine (at least three doses)
Study: 26240957
Drug: Group singing
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group singing therapy
Study: 23396206
Drug: Low-dose JX-594
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose JX-594
Study: 23396206
Drug: High-dose JX-594
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose JX-594
Study: 21446376
Drug: Intra-arterial lidocaine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial lidocaine (20 mg)
Study: 17679043
Drug: ramipril at
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ramipril at 10 mg
Study: 17679043
Drug: atenolol at
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atenolol at 100 mg
Study: 11228370
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated measles vaccine (Hu191)
Study: 8067495
Drug: 40-60 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-60 mg/day of fluoxetine
Study: 8067495
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of fluoxetine plus 300-600 mg/day of lithium
Study: 8067495
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of fluoxetine plus 25-50 mg/day of desipramine
Study: 25180722
Drug: Increasing insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing insulin dose
Study: 25180722
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients (conventional therapy)
Study: 23271777
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment for clinically localized prostate cancer
Study: 17447116
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg once daily for 1 year
Study: 17447116
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no pharmacotherapy)
Study: 9851950
Drug: Streptokinase (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1.5 million units, single intravenous infusion)
Study: 7989941
Drug: 175 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg/m2 of Taxol over 24 hours
Study: 7989941
Drug: 135 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg/m2 of Taxol over 24 hours
Study: 7989941
Drug: Taxol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol administered as a 3-hour infusion
Study: 7989941
Drug: Taxol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol administered as a 24-hour infusion
Study: 7989941
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion
Study: 2927639
Drug: Lisuride +
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride + low dose levodopa
Study: 28007576
Drug: Rifaximin-EIR (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin-EIR (400 mg)
Study: 26423649
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitor monotherapy (PI-mono)
Study: 14749158
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (150 mg twice daily)
Study: 11257560
Drug: RAD 0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD 0.035 mg/kg (2.5 mg maximum)
Study: 11257560
Drug: RAD 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD 0.10 mg/kg (7.5 mg maximum)
Study: 11257560
Drug: RAD (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD (both doses)
Study: 11257560
Drug: RAD (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD (higher dose)